АШУҮИС — Судалгааны мэдээлэл (CRIS)
Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001
Browse
18 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prevalence of viral infection and its impact on early-stage hepatocellular carcinoma: Insights from Mongolia, a developing country(Elsevier BV, 2026-07-30); ;Tsendjav Tsogtbaatar; ; Yumchinserchin Narangerel, Tsendjav Tsogtbaatar, Gonchigsuren Dagvasumberel, Dashkhorol Davaadorj, Enebish Sundui and Adilsaikhan Mendjargal. Int J Gastrointest Interv -0001;0:. https://doi.org/10.18528/ijgii260007 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The Impact of GPC3 rs2267531 Polymorphism on Hepatocellular Carcinoma Susceptibility(Mongolian National University of Medical Sciences, 2025-03-31); ;Yesukhei Enkhbat ;Odonchimeg Tuvshiunsaikhan ;Yundendash DashzevegMunkhtsetseg Bat-ErdeneObjectives: To evaluate the association between the GPC3 rs2267531 polymorphism and hepatocellular carcinoma (HCC) in individuals from Mongolia. Methods: This study included 270 participants, consisting of 110 males and 160 females, with a mean age of 61.0 years (±9.5). Serum samples were collected from all participants, who were categorized into three groups: 90 patients with hepatocellular carcinoma (HCC), 90 individuals in the risk group (RG), and 90 healthy controls. The collected samples were analyzed using allele-specific polymerase chain reaction (PCR). Results: No significant differences in genotype and allele frequencies were observed between the HCC group and the risk or control groups. However, the frequency of the GPC3 C allele was significantly higher in females in the HCC group. Additionally, the protective GG genotype of GPC3 was found to have a significantly lower frequency in females in the HCC group. In contrast, HCV-positive individuals exhibited a higher frequency of the GC genotype. Conclusion: The GPC3 C allele frequency is associated with HCC in females, while the heterozygote GC genotype is linked to HCV infection in both genders. These findings suggest that the GPC3 rs2267531 polymorphism may play a role in HCC susceptibility, particularly in relation to gender and HCV status. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Variables Influencing 6-Month Relapse in Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation(Mongolian National University of Medical Sciences, 2024-03-12); ; ; Objectives: Hepatocellular carcinoma (HCC) emerged as a global health concern in 2020, ranking as the sixth most diagnosed cancer and the third leading cause of cancer-related death. This study analyzed predictors of 6-month relapse in early-stage HCC patients after Radiofrequency Ablation (RFA). Methods: This retrospective study, from January 1, 2018, to December 31, 2022, meticulously explored ablation methods for early-stage HCC treatment. Data collection included a 6-month relapse definition, demographic details, and tumor-related variables. Results: Over five years, 483 participants underwent RFA for early-stage HCC, presenting diverse demographic and tumor-related profiles. Significant associations were found between relapse and factors such as gender, smoking, alcohol use, tumor size, specific tumor locations, and pre-treatment AST levels. Notably, 6.8% of participants experienced relapse within six months. In the multivariate analysis, adjusting for confounders, smoking (p = 0.014), tumor size > 3cm (p < 0.001), tumor location S2 (p < 0.001), and pre-treatment AST levels (p = 0.015) remained significant predictors. Conclusion: This study sheds light on the complex dynamics of 6-month relapse in early-stage HCC patients, emphasizing the significance of predictors such as smoking, tumor size, tumor location, and pre-treatment AST levels. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P.353: Impact factors leading to renal impairment after liver transplantation: a single center consecutive 12 years’ experience.(Wolters Kluwer, 2024-09-01); ; ;Chuluunbileg Batbold ;Fidel López‐VerdugoJade M. NunezIntroduction: Renal impairment (RI) is a common life-threatening complication of cirrhosis, affecting one in every five patients. Although LT is a lifeline for cirrhotic patients with impaired renal function, postoperative acute RI is not uncommon and is influenced by multiple factors, leading to poor outcomes. Hepatitis B virus (HBV) infection has been associated with increased risk of developing chronic kidney disease in some studies. The potential role of HBV infection in post-LT RI is unknown. This is likely due to the low prevalence of HBV infection amongst liver transplant recipients, which has been reported to be around 5% in the USA. Low- and Middle income country like Mongolia has the highest rate of hepatocellular carcinoma and hepatitis B in the world. Mongolian First liver transplant (LT) performed at First Central Hospital of Mongolia (FCHM) in September 2011 in a collaborative effort with South Korea’s Asan Medical Center. In this context, the aim of our study is identify the role of HBV infection on the incidence of renal impairment after liver transplantation. We hypothesize that patients with HBV infection will have a higher rate of RI post-LT. Methods: To determine the changes of renal function of peri- and post-LT as well as to identify risk factors for RI, we analyzed the First Central Hospital of Mongolia (FCHM) Liver Transplantation Database retrospectively, which includes patients who received LT between September 21, 2011, and December 31, 2022. Early RI was identified by measuring glomerular filtration rates by Cockcroft-Gault creatinine clearance formulation at pretransplantation, intraoperatively, 24h, 72h, 7d, 14d and 28d post LT. Results: The results revealed that female gender (OR=3.06; 95% CI=1.58–5.91), Child-Tucotte-Pugh (CTP) score B and C (OR=4.23; 95% CI=0.92–19.41), (OR=7.68; 95% CI=1.67–35.30), preoperative continuous renal replacement therapy (CRRT) (OR=5.86; 95% CI=1.1–31.21), high graft to recipient weight ratio (GRWR) (OR=3.45; 95% CI=1.23–9.63) increased the risk of RI among recipients. Moreover, recipients’ age (OR=1.07; 95% CI=1.03–1.11), Model for End-Stage Liver Disease (MELD) score (OR=1.09; 95% CI=1.03–1.16), intraoperative leukoreduced red blood cells (LR-RBC) (OR=1.09; 95% CI=1.04–1.14), platelet (PLT) (OR=1.06; 95% CI=1.00–1.12+), fresh frozen plasma (FFP) (OR=1.07; 95% CI=1.02–1.11) and postoperative LR-RBC (OR=1.09; 95% CI=1.04–1.14), cryoprecipitate transfusion (OR=1.1; 95% CI=1.01–1.19), intubated hours (OR=1.04; 95% CI=1.01–1.07) increased slightly the risk of RI. Conclusions: Female gender, high Child Pugh score, preoperative CRRT and high graft to recipient weight ratio are the primary risk factors RI after liver transplant surgery in Mongolia. The liver transplantation team at the FCHM expresses our gratitude to Prof. Sung-Gyu Lee and Liver transplantation team from the Asan Medical Center, Seoul, South Korea. Their contribution was invaluable in the form of guidance and precious knowledge transfer for developing the robust liver transplantation program in Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P.389: No difference in recurrent hepatocellular carcinoma rates in liver transplanted patients receiving mTOR inhibitors compared to non-mTOR group.(Wolters Kluwer, 2024-09-01) ;Anar Ganbold ;Margad-Erdene Erdenechuluun ;Bayarmaa Ochirkhuree ;Urnultsaikhan GanboldUlzii-Orshikh NamkhaiIntroduction: A liver transplantation (LT) is a first line therapeutic choice for patients with hepatocellular carcinoma (HCC). Mammalian Target of Rapamycin (mTOR) inhibitors act as immunosuppressant and indicated against HCC recurrence in LT patients. The efficacy of mTOR inhibitors in preventing HCC recurrence remains contentious. Methods: We retrospectively enrolled 45 patients (average age 50, M/F:29/16) who had a history of HCC at the time of LT operation at a single center (2011-2023) and divided into a mTOR and non-mTOR groups. Initial Alfa-fetoprotein (AFP), Protein induced by vitamin K absence-II (PIVKA-II) levels, contrast-enhanced abdominal computer-assisted tomography (CT) scans were compared to most recent results, explant histology was also assessed for HCC extent. Decision to transplant was made based on Milan criteria. Student t-test was used to determine statistical significance (p<0.05). Results: In the mTOR group (n=23, average age 52.7) there were 2 confirmed HCC recurrences with elevated markers and positive CT scans. In the non-mTOR group (n=22, average age 47.4) there was 1 confirmed case of HCC. A recurrence rate of 6.67% was recorded overall, 8.7% and 4.55% for mTOR and non-mTOR (p=0.28), respectively. All three recurrences were detected within 24 months of the operation. For recurrent HCCs, the average levels of PIVKA-II and AFP were 27010mAU/ml and 2842.7ng/ml, respectively. There was no difference in number and mode of pre-LT bridging therapies (TACE or RFA) with regards to recurrence. There were two cases of elevated PIVKA-II without a radiologic confirmation. Conclusion: Adherence to the Milan criteria and application of pre-LT bridging therapies will keep the recurrence rate below 10%. Any possible recurrence will be diagnosed within 24 months of LT. Administration of mTOR inhibitors can be stopped after 2 years as part of the physician-guided minimization of immune suppression regimen. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P.367: Outcomes of liver transplantation: A single-center experience. (First Central Hospital of Mongolia).(Wolters Kluwer, 2024-09-01); ; ; ; Methods: This study was conducted in Transplantation Center of the First Central Hospital of Mongolia between September 2011 and May 2023 on a total 200 patients have undergone liver transplantation. Results: There were 105 female patients out of 200, age between 18 months to 62 years old, and the average MELD score was 15±5.5, length of hospital stay were 31±13.94. These transplants were for liver (living donor=189, deceased donor=11, pediatric=7). The most causes of liver transplantation were liver cirrhosis due to HBV/HDV (59.5%), hepatocellular carcinoma (22.5%), primary biliary cirrhosis (5%), and only HBV related cirrhosis, alcoholic cirrhosis. There were 23(11.5%) biliary complication, 17 (8.5%) acute cellular rejection, hepatic artery thrombosis 2 (1%), and 3 cases retransplanted. The five year survival was 87%. Conclusions: This study provides the process of liver transplantation in First Central Hospital of Mongolia, and these positive outcomes support LT as an important therapy for end-stage liver disease and early hepatocellular carcinomas. Introduction: Liver transplantation (LT) is a main treatment of end-stage liver disease. Specially developing country like Mongolia has high prevalence of HBV, HDV, and hepatocellular cancer. Liver transplant is the second-most common solid organ transplant procedure in Mongolia. This study aimed to evaluate the efficacy of liver transplantation in the First Central Hospital of Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Treatment of Chronic HCV Infection with Direct Acting Antivirals(Mongolian National University of Medical Sciences, 2021-09-21) ;Bekhbold Dashtseren ;Zulkhuu Genden ;Odgerel Oidovsambuu ;Anir EnkhbatGanbolor JargalsaikhanObjectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs). Methods: Based on the Liver Center database, we studied the treatment effect of Sofosbuvir 400 mg/Ledipasvir 90 mg in 1109 patients with chronic hepatitis C virus infection during the time period from December 2015 to December, 2018. Results: In patients treated with Sofosbuvir/Ledipasvir, the sustained viral load (SVR12) was 97.9% (1086/1109) 12 weeks after the treatment. The SVR12 was 99.2% (845/851) in HCV-infected non-cirrhotic patients, 93.4% (241/258) in patients with cirrhosis, and 80% (8/10) among patients treated for liver cancer. The SVR12 (19/25) was lowered to 76% at 12 weeks of treatment with Sofosbuvir 400 mg/ Daclatasvir 60 mg in DAA-failure patients 23/1109 (2.07%). Conclusions: SVR12 rates in non-cirrhotic and cirrhotic patients were 99.2% and 93.4%, respectively, while it was 80% in liver cancer patients after DAA treatment. As for patients with viral relapse, 76% of them were successfully retreated with second-line DAA treatment. During the DAA treatment, only 17.6% of all patients had some adverse effects related to DAA treatment, thus, DAA treatment is suitable for Mongolian patients and has less adverse effects. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Renal Dysfunction After Liver Transplantation: a Single Center Study(Mongolian National University of Medical Sciences, 2021-12-31); ;Fidel López‐Verdugo; ;Suvd NerguiObjectives: Mongolia is known as one of the countries with a high prevalence of viral hepatitis infection and its related liver cirrhosis and HCC. Therefor, liver transplantation (LT) surgery increases from year to year in Mongolia. Our goal was to evaluate post-transplant renal dysfunction (PTRD) and to investigate the predicting factors for renal dysfunction after LT. Methods: The impact of graft ischemic time, peri- and postoperative blood product transfusion, perioperative hemodynamics, time to extubating, intensive care length of stay, incidence of chronic renal failure, and mortality and morbidity were examined alone and then as a combined outcome. Results: Early renal dysfunction was identified by measuring serum creatinine and glomerular filtration rate. In our investigation which was a study group of patients following liver transplantation (LT), the following renal dysfunctions were found: 39% of recipients in the study had renal dysfunction, while the rest had no renal dysfunction. The average creatinine level of the recipients who had a renal dysfunction after LT, was 0.825 ± 0.24 mg/dl and the glomerular filtration rate was 111 ± 36.3 ml/min, and statistically significant. Conclusion: Preoperative kidney function plays a crucial role for postoperative renal dysfunction. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison of Adverse Events Between Selective Internal Radiation Therapy Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma in Mongolia: A Subgroup Analysis of SIRveNIB Study(Mongolian National University of Medical Sciences, 2017-11-25); ; ;Bolormaa Yalhgar ;Tuyatsetseg AltankhuyagObjective: This study compared the adverse events associated with selective internal radiation therapy to sorafenib in the treatment of patients with locally advanced hepatocellular carcinoma (HCC). Methods: From March 2011 to June 2106, the National Cancer Center of Mongolia recruited 39 patients from Mongolia (19 received sorafenib and 20 received SIRT in Singapore) with advanced hepatocellular carcinoma who had not received surgical therapy into a multicenter study involving a total of 360 patients at 27 sites in 11 Asia-Pacific countries. The study was a phase III randomized-controlled clinical trial comparing sorafenib or SIRT. Results: Adverse events for patients receiving sorafenib were predominantly grade 1 or 2 in gastrointestinal, constitutional and dermatologic in nature. The most frequently reported drug-related adverse events in patients treated with sorafenib were hypertension, hand-foot skin reaction, diarrhea, alopecia, fatigue. Common procedure-related adverse events were usually mild (grade 1/2) and included nausea and vomiting (27.7% all grades) and abdominal pain (22.1% all grades), with very few grades 3 or greater adverse events. Conclusion: In our analysis of 39 patients, we were unable to detect a statistically significant difference in adverse effects between sorafenib and SIRT treatment groups, likely because there were insufficient number patients in our study. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, For the right hemiliver graft may need tissue expander after living donor liver transplantation(2020-12-01)The number of liver transplantation (LT) increases last few years, which is related with populating the high surgical technology in developing country like in Mongolia. The main reason of LT is a hepatitis B virus-related liver cirrhosis in Mongolia. LT had started since 2011 under the support of Professor Sung Gyu Lee from hepatobiliary surgery and LT of Asan Medical Center. Veno-occlusive disease, Budd-Chiari syndrome, and congestive hepatopathy, all of which results in hepatic venous outflow obstruction (HVOO). The early HVOO is rare, however that could raise a serious complication as a graft failure and eventual lose. We report a case of early HVOO, which may result of size mismatch of abdominal cavity. Acute cellular rejection of liver allograft may influenced due to graft malposition, which unsized upper part of abdomen between donor and recipient after living donor LT. The size mismatch of body may produce kinking syndrome after right lobe living donor LT, which reveals the HVOO without anastomosis complication. Methods: A 38-year-old male patient with liver cirrhosis due to hepatitis B virus, HDV, hepatocellular carcinoma in S8 of the liver (Child-Pugh score-B, Model For End-Stage Liver Disease-18). On the first postoperative day the patient developed impairment of the liver function. Doppler ultrasound showed the different speed of right hepatic vein preanastomosis and postanastomosis field. This was diagnosed acute liver failure due to veno-oclusive disease, after that started intensive therapy. Results: Kinking or twisting of the venous anastomosis is related with anatomical mismatch between the graft and the recipient abdomen, even though transplanted the right hemiliver graft. HVOO results acute cellular rejection, which treated by pulse therapy. However it should be managed by surgically, put the tissue expander. Conclusions: We report the right graft needs the tissue expander for mismatching between the graft and recipient abdomen.
